Fighting Fire with Fire: Phage Potential for the Treatment of E. coli O157 Infection.
Antibiotics (Basel)
; 7(4)2018 Nov 16.
Article
em En
| MEDLINE
| ID: mdl-30453470
ABSTRACT
Hemolyticâ»uremic syndrome is a life-threating disease most often associated with Shiga toxin-producing microorganisms like Escherichia coli (STEC), including E. coli O157H7. Shiga toxin is encoded by resident prophages present within this bacterium, and both its production and release depend on the induction of Shiga toxin-encoding prophages. Consequently, treatment of STEC infections tend to be largely supportive rather than antibacterial, in part due to concerns about exacerbating such prophage induction. Here we explore STEC O157H7 prophage induction in vitro as it pertains to phage therapy-the application of bacteriophages as antibacterial agents to treat bacterial infections-to curtail prophage induction events, while also reducing STEC O157H7 presence. We observed that cultures treated with strictly lytic phages, despite being lysed, produce substantially fewer Shiga toxin-encoding temperate-phage virions than untreated STEC controls. We therefore suggest that phage therapy could have utility as a prophylactic treatment of individuals suspected of having been recently exposed to STEC, especially if prophage induction and by extension Shiga toxin production is not exacerbated.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
Antibiotics (Basel)
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Estados Unidos